Drugs Made In America Acquisition Corp. (DMAA) Form 10-Q Quarterly Reports
Drugs Made In America Acquisition Corp. (DMAA) is a publicly traded company on the Nasdaq, categorized under SIC 6770 (Blank Checks). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: DMAA
CIK: 2028614
Exchange: Nasdaq
SIC 6770: Blank Checks
Fiscal Year End: 12/31
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
MaloneBailey, LLP
Auditor SinceSince 6/30/2024 12:00:00 AM
Lead Engagement PartnerGeorge Qin
Audit LocationHouston, Texas, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 425 | 2026-09-14 | — | CURRENT REPORT | 0001213900-26-099743 | View SEC Doc Filr Page |
| 8-K | 2026-09-14 | 2026-09-08 | CURRENT REPORT | 0001213900-26-099738 | View SEC Doc Filr Page |
| 10-Q | 2026-08-14 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-090035 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001072613-26-000664 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001604488-26-000087 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-13 | — | SCHEDULE 13G/A Filing | 0001076809-26-000079 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-13 | — | SCHEDULE 13G/A Filing | 0001104659-26-095396 | View SEC Doc Filr Page |
| 425 | 2026-07-20 | — | CURRENT REPORT | 0001213900-26-079686 | View SEC Doc Filr Page |
| 8-K | 2026-07-20 | 2026-07-14 | CURRENT REPORT | 0001213900-26-079678 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-06-26 | — | SCHEDULE 13G Filing | 0001376474-26-000460 | View SEC Doc Filr Page |
| 10-Q | 2026-05-14 | 2026-03-31 | QUARTERLY REPORT | 0001213900-26-056798 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-05-14 | — | SCHEDULE 13G Filing | 0001104659-26-060643 | View SEC Doc Filr Page |
| 425 | 2026-05-05 | — | CURRENT REPORT | 0001213900-26-052331 | View SEC Doc Filr Page |
| 8-K | 2026-05-05 | 2026-04-29 | CURRENT REPORT | 0001213900-26-052324 | View SEC Doc Filr Page |
| 8-K | 2026-05-01 | 2026-04-27 | CURRENT REPORT | 0001213900-26-051018 | View SEC Doc Filr Page |
| 8-K | 2026-04-28 | 2026-04-22 | CURRENT REPORT | 0001213900-26-048585 | View SEC Doc Filr Page |
| DEFR14A | 2026-04-16 | — | REVISED DEFINITIVE PROXY STATEMENT | 0001213900-26-044631 | View SEC Doc Filr Page |
| 10-K | 2026-04-15 | 2025-12-31 | ANNUAL REPORT | 0001213900-26-044139 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-14 | 2026-04-27 | PROXY STATEMENT | 0001213900-26-043527 | View SEC Doc Filr Page |
| 8-K | 2026-04-08 | 2026-04-07 | CURRENT REPORT | 0001213900-26-041284 | View SEC Doc Filr Page |
| NT 10-K | 2026-04-01 | 2025-12-31 | NOTIFICATION OF LATE FILING | 0001213900-26-038499 | View SEC Doc Filr Page |
| PRE 14A | 2026-03-27 | 2026-03-27 | PROXY STATEMENT | 0001213900-26-035624 | View SEC Doc Filr Page |
| 8-K | 2026-03-27 | 2026-03-23 | CURRENT REPORT | 0001213900-26-035502 | View SEC Doc Filr Page |
| 8-K | 2026-03-06 | 2026-03-06 | CURRENT REPORT | 0001213900-26-024762 | View SEC Doc Filr Page |
| 8-K | 2026-03-06 | 2026-02-28 | CURRENT REPORT | 0001213900-26-024392 | View SEC Doc Filr Page |